They found that elevated expression of ABCG2 was signature for the patients that didn’t respond to chemotherapy and for cases with shorter progression-free survival time in a 2.5 years follow-up and concluded that ABCG2 may be a crucial factor in primary resistance of non-Hodgkin’s lymphomas. The gene discussed is ABCG2; the disease is non-Hodgkin lymphoma.